FTC Denies Violations In Watson Pay-To-Delay Probe

Law360, New York (July 22, 2010, 7:34 PM EDT) -- The Federal Trade Commission argued Thursday that it did nothing wrong in its antitrust investigation of a patent settlement between Watson Pharmaceuticals Inc. and Cephalon Inc., in a suit seeking to force Watson CEO Paul M. Bisaro to testify in the probe.

The FTC denied that it had attempted to “broker a deal” between Watson and rival Apotex Inc. or disclosed confidential information during the investigation, and asked the U.S. District Court for the District of Columbia to enforce a subpoena against Bisaro.

In 2009, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.